Correction to: Nature Biotechnology https://doi.org/10.1038/s41587-021-01115-y, published online 9 November 2021.
This News article has been updated to reflect that AstraZeneca is pursuing a Treg cell therapy research program, not CAR-Treg, and that the company’s validation experiments following a genome-wide screen looking for additional factors that can help ensure a consistent Treg phenotype are at the planning stage, not ongoing, as the article states.
The online version of the article has been updated.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dolgin, E. Publisher Correction: Treg engineers take aim at autoimmunity. Nat Biotechnol 40, 131 (2022). https://doi.org/10.1038/s41587-021-01200-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-021-01200-2
